The lawsuit surrounding Ozempic and Wegovy is intensifying as more patients report serious complications from these GLP-1 receptor agonists, commonly prescribed for weight loss and diabetes control
Almost all are administered subcutaneously, although oral semaglutide is currently available in Spain (see below)
Deacon CF: Circulation and degradation of GIP and GLP-1
Diabetes Obes Metab 19(3):33647 Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH et al (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
Research indicates that GLP-1RAs can decrease the expression of pro-inflammatory cytokines like TNF-, which plays a pivotal role in PsA pathogenesis